Healthcare Earnings: Demand Surges, Costs Bite Back
Healthcare and pharma companies described broad-based patient and prescription demand alongside investment-heavy capex plans, even as input costs emerged as the one category tilting negative.
Demand was the dominant note of the 2026 second quarter across healthcare and pharma, with 341 of 406 tracked references positive and only 45 negative. AbCellera Biologics (ABCL) signed two new T-cell engager collaborations with Jazz and Vertex worth over $100 million in upfront cash. Acadia Pharmaceuticals (ACAD) pointed to strong patient demand and uptake of the STIX formulation of DAYBUE, alongside momentum in new-to-brand prescriptions for NUPLAZID following a sales force expansion. Acadia Healthcare Company (ACHC) reported same-facility patient days up 0.8%, evidence that demand strength extended from specialty biotech into hospital operators.
Outlook commentary tracked the same direction, with 361 of 497 references positive versus 34 negative. AbbVie (ABBV) called its long-term outlook "very strong," and Acadia Pharmaceuticals raised its full-year 2026 revenue guidance to $1.24 to $1.30 billion. The 93 neutral outlook references were concentrated in pipeline timing rather than caution about guidance, with AbCellera flagging Phase 2 data for ABCL635 in August and Phase 1 data for ABCL575 in the fourth quarter.
Capital spending mirrored that confidence: 91 positive references against just 6 negative. AbbVie framed its proposed acquisition of Apogee Therapeutics as bolstering its immunology leadership, while Acadia Healthcare added 240 licensed beds from newly constructed facilities during the quarter. Arcutis Biotherapeutics (ARQT) completed hiring a specialized sales team for primary care and pediatric providers ahead of an August field launch, tying investment directly to near-term commercial execution.
The clearest cross-current sat in input costs, the only category where negative references outnumbered positive ones, 125 to 107. Aclaris Therapeutics (ACRS) cited higher research and development spending tied to manufacturing and clinical costs for its ATI-052 and ATI-9494 programs, plus rising legal and personnel expenses in its general and administrative line. Adaptive Biotechnologies (ADPT) guided full-year operating expenses, including cost of revenue, to a $350 million to $355 million range, underscoring that cost discipline is now a standing agenda item even for companies reporting solid demand.
Pricing power stayed net positive overall (56 versus 19 negative) but showed real friction. Adma Biologics (ADMA) expects sustained competitive dynamics and pricing pressure in the U.S. immune globulin market through year-end, and Acadia Healthcare's revenue per patient day fell 0.8% on the timing of state supplemental payments. Hiring was the most evenly split category, 27 positive against 23 negative: AdaptHealth (AHCO) completed a workforce restructuring generating $19 million in annualized savings, while Alector (ALEC) cut research and administrative costs through reductions in force even as commercial-stage names like Arcutis kept adding sales headcount.
Taken together, the quarter's message from healthcare and pharma was that patient and prescription demand remains broad and companies are willing to spend against it, but managing input cost inflation is now the swing factor separating steady execution from margin pressure.